share_log

Goldman Sachs Maintains Neutral on Phathom Pharmaceuticals, Raises Price Target to $12

Benzinga ·  Aug 9 08:49

Goldman Sachs analyst Paul Choi maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Neutral and raises the price target from $10 to $12.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment